Showing 1 - 5 results of 5 for search 'Yasuhiro Koh', query time: 0.02s Refine Results
  1. 1
    Comparison of the Immune Checkpoint Inhibitor‐Free Survival Between Patients Who Completed and Those Who Discontinued ICI for Non‐Small Cell Lung Cancer

    Comparison of the Immune Checkpoint Inhibitor‐Free Survival Between Patients Who Completed and Those Who Discontinued ICI for Non‐Small Cell Lung Cancer by Takahiro Nagai, Hiroaki Akamatsu, Eri Takase, Eriko Murakami, Takeya Sugimoto, Ryota Shibaki, Atsushi Hayata, Toshio Shimizu, Masanori Nakanishi, Yasuhiro Koh, Nobuyuki Yamamoto

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Development of an automated size-based filtration system for isolation of circulating tumor cells in lung cancer patients.

    Development of an automated size-based filtration system for isolation of circulating tumor cells in lung cancer patients. by Satomi Yagi, Yasuhiro Koh, Hiroaki Akamatsu, Kuninobu Kanai, Atsushi Hayata, Nahomi Tokudome, Keiichiro Akamatsu, Katsuya Endo, Seita Nakamura, Masayuki Higuchi, Hisashige Kanbara, Masanori Nakanishi, Hiroki Ueda, Nobuyuki Yamamoto

    Published 2017-01-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Can smoking duration alone replace pack-years to predict the risk of smoking-related oncogenic mutations in non-small cell lung cancer? A cross-sectional study in Japan

    Can smoking duration alone replace pack-years to predict the risk of smoking-related oncogenic mutations in non-small cell lung cancer? A cross-sectional study in Japan by Masahiko Ando, Yoshihiko Taniguchi, Akihiro Tamiya, Akihide Matsumura, Koichi Ogawa, Yasuhiro Koh, Hiroyasu Kaneda, Motohiro Izumi, Yoshiya Matsumoto, Kenji Sawa, Mitsuru Fukui, Naoki Yoshimoto, Akihito Kubo, Shun-ichi Isa, Hideo Saka, Tomoya Kawaguchi

    Published 2020-09-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Circulating Tumour DNA in Patients With EGFR‐Mutated Non‐Small‐Cell Lung Cancer and Early Disease Progression After First‐Line Osimertinib Treatment: The ELUCIDATOR Multicentre Prospective Observational Study

    Circulating Tumour DNA in Patients With EGFR‐Mutated Non‐Small‐Cell Lung Cancer and Early Disease Progression After First‐Line Osimertinib Treatment: The ELUCIDATOR Multicentre Pro... by Akihiro Tamiya, Yasuyuki Mizumori, Mitsuo Osuga, Shun‐ichi Isa, Yoshihiko Taniguchi, Keiichi Nakamura, Daijiro Harada, Tsutomu Shinohara, Hidetoshi Yanai, Katsumi Nakatomi, Masahide Oki, Masahide Mori, Tomohito Kuwako, Koji Yamazaki, Atsuhisa Tamura, Masahiko Ando, Yasuhiro Koh

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer

    Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer by Hirotaka Matsumoto, Hiroaki Akamatsu, Nobuyuki Yamamoto, Yuki Sato, Daichi Fujimoto, Yoshihiko Taniguchi, Motohiro Tamiya, Yasuhiro Koh, Junya Fukuoka, Hisashi Tanaka, Naoki Furuya, Ryota Shibaki, Tsukasa Nozawa, Akira Sano, Yuka Kitamura, Takashi Kijima, Toshihide Yokoyama, Satoru Miura, Akito Hata, Jun Sugisaka

    Published 2024-02-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: